Goldman Sachs
ALXO icon

Goldman Sachs’s ALX Oncology ALXO Stock Holding History

Goldman Sachs’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
742,331
+603,738
+436% +$1.08M ﹤0.01% 4882
2026
Q1 		$278K Buy
138,593
+121,331
+703% +$231K ﹤0.01% 5933
2025
Q4 		$19.5K Sell
17,262
-1,332
-7% -$2.02K ﹤0.01% 6344
2025
Q3 		$34K Sell
18,594
-271,099
-94% -$235K ﹤0.01% 6206
2025
Q2 		$120K Sell
289,693
-83,521
-22% -$42.2K ﹤0.01% 5782
2025
Q1 		$233K Sell
373,214
-195,795
-34% -$235K ﹤0.01% 5573
2024
Q4 		$950K Buy
569,009
+312,130
+122% +$480K ﹤0.01% 4855
2024
Q3 		$468K Buy
256,879
+41,627
+19% +$155K ﹤0.01% 5087
2024
Q2 		$1.3M Buy
215,252
+58,250
+37% +$716K ﹤0.01% 4272
2024
Q1 		$1.75M Buy
157,002
+66,259
+73% +$931K ﹤0.01% 3957
2023
Q4 		$1.35M Sell
90,743
-40,384
-31% -$383K ﹤0.01% 4209
2023
Q3 		$629K Sell
131,127
-48,640
-27% -$264K ﹤0.01% 4537
2023
Q2 		$1.35M Sell
179,767
-880
-0.5% -$5.76K ﹤0.01% 4142
2023
Q1 		$817K Buy
180,647
+5,186
+3% +$39.3K ﹤0.01% 4529
2022
Q4 		$1.98M Buy
175,461
+14,715
+9% +$165K ﹤0.01% 3953
2022
Q3 		$1.54M Sell
160,746
-86,997
-35% -$1.01M ﹤0.01% 4193
2022
Q2 		$2M Buy
247,743
+33,257
+16% +$362K ﹤0.01% 4057
2022
Q1 		$3.62M Buy
214,486
+75,348
+54% +$1.29M ﹤0.01% 3648
2021
Q4 		$2.99M Sell
139,138
-23,858
-15% -$1.03M ﹤0.01% 3888
2021
Q3 		$12M Buy
162,996
+26,663
+20% +$1.78M ﹤0.01% 2538
2021
Q2 		$7.46M Sell
136,333
-117,052
-46% -$7M ﹤0.01% 2980
2021
Q1 		$18.7M Buy
253,385
+121,757
+93% +$9.6M ﹤0.01% 1994
2020
Q4 		$11.3M Buy
131,628
+124,247
+1,683% +$7.47M ﹤0.01% 2355
2020
Q3 		$279K Buy
+7,381
New +$290K ﹤0.01% 4773

Other funds holding ALXO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
venBio Partners
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Redmile Group
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Goldman Sachs's ALXO Position: Q2 2026 in Review

Goldman Sachs increased its ALX Oncology (ALXO) stake by 436% in Q2 2026, buying an estimated $1.08M and bringing the position to 742,331 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4882.

Goldman Sachs first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $18.7M in Q1 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Goldman Sachs held 742,331 shares of ALX Oncology worth $1.54M as of Q2 2026.
  • Goldman Sachs bought 603,738 ALX Oncology shares in Q2 2026, an estimated $1.08M.
  • ALX Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4882 holding.
  • Goldman Sachs first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Goldman Sachs's ALX Oncology position peaked at $18.7M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.